Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Measuring viability selection from prospective cohort mortality studies: A case study in maritime pine.

Robledo-Arnuncio JJ, Unger GM.

Evol Appl. 2019 Mar 18;12(5):863-877. doi: 10.1111/eva.12729. eCollection 2019 Jun.

2.

Novel Modal Approximation Scheme for Plasmonic Transmission Problems.

Unger G, Trügler A, Hohenester U.

Phys Rev Lett. 2018 Dec 14;121(24):246802. doi: 10.1103/PhysRevLett.121.246802.

PMID:
30608724
3.

Preanalytical phase: Effects of water ingestion during fasting on routine hematological parameters in a small cohort of young women.

Unger G, Benozzi SF, Campion A, Pennacchiotti GL.

Clin Chim Acta. 2018 Aug;483:126-129. doi: 10.1016/j.cca.2018.04.019. Epub 2018 Apr 17.

PMID:
29678633
4.

Fasting conditions: Influence of water intake on clinical chemistry analytes.

Benozzi SF, Unger G, Campion A, Pennacchiotti GL.

Biochem Med (Zagreb). 2018 Feb 15;28(1):010702. doi: 10.11613/BM.2018.010702. Epub 2017 Nov 24.

5.

Evaluation of protein kinase CK2 as a therapeutic target for squamous cell carcinoma of cats.

Cannon CM, Trembley JH, Kren BT, Unger GM, O'Sullivan MG, Cornax I, Modiano JF, Ahmed K.

Am J Vet Res. 2017 Aug;78(8):946-953. doi: 10.2460/ajvr.78.8.946.

6.

Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.

Cannon CM, Trembley JH, Kren BT, Unger GM, O'Sullivan MG, Cornax I, Modiano JF, Ahmed K.

Hum Gene Ther Clin Dev. 2017 Jun;28(2):80-86. doi: 10.1089/humc.2017.008. Epub 2017 Mar 23.

7.

CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.

Trembley JH, Kren BT, Abedin MJ, Vogel RI, Cannon CM, Unger GM, Ahmed K.

Pharmaceuticals (Basel). 2017 Feb 21;10(1). pii: E25. doi: 10.3390/ph10010025. Review.

8.

CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.

Ahmed K, Kren BT, Abedin MJ, Vogel RI, Shaughnessy DP, Nacusi L, Korman VL, Li Y, Dehm SM, Zimmerman CL, Niehans GA, Unger GM, Trembley JH.

Oncotarget. 2016 Sep 20;7(38):61789-61805. doi: 10.18632/oncotarget.11442.

9.

Assessing early fitness consequences of exotic gene flow in the wild: a field study with Iberian pine relicts.

Unger GM, Heuertz M, Vendramin GG, Robledo-Arnuncio JJ.

Evol Appl. 2016 Jan 9;9(2):367-80. doi: 10.1111/eva.12333. eCollection 2016 Feb.

10.

Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.

Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.

Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0. Epub 2015 Feb 11.

11.

Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice.

Trembley JH, Unger GM, Korman VL, Abedin MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT, Ahmed K.

PLoS One. 2014 Oct 15;9(10):e109970. doi: 10.1371/journal.pone.0109970. eCollection 2014.

12.

Estimating exotic gene flow into native pine stands: zygotic vs. gametic components.

Unger GM, Vendramin GG, Robledo-Arnuncio JJ.

Mol Ecol. 2014 Nov;23(22):5435-47. doi: 10.1111/mec.12946. Epub 2014 Oct 21.

PMID:
25277767
13.

Triglycerides and glucose index: a useful indicator of insulin resistance.

Unger G, Benozzi SF, Perruzza F, Pennacchiotti GL.

Endocrinol Nutr. 2014 Dec;61(10):533-40. doi: 10.1016/j.endonu.2014.06.009. Epub 2014 Aug 28. English, Spanish.

PMID:
25174769
14.

High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantation.

Egger F, Nürnberg M, Rohla M, Weiss TW, Unger G, Smetana P, Geppert A, Gruber SC, Bambazek A, Falkensammer J, Waldenberger FR, Huber K, Freynhofer MK.

Heart Rhythm. 2014 Dec;11(12):2176-82. doi: 10.1016/j.hrthm.2014.07.014. Epub 2014 Jul 14.

15.

Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

Unger GM, Kren BT, Korman VL, Kimbrough TG, Vogel RI, Ondrey FG, Trembley JH, Ahmed K.

Mol Cancer Ther. 2014 Aug;13(8):2018-29. doi: 10.1158/1535-7163.MCT-14-0166. Epub 2014 May 27.

16.

Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromes.

Tentzeris I, Rohla M, Jarai R, Farhan S, Freynhofer MK, Unger G, Nürnberg M, Geppert A, Wessely E, Wojta J, Huber K.

Am J Cardiol. 2014 Apr 1;113(7):1099-104. doi: 10.1016/j.amjcard.2013.12.012. Epub 2014 Jan 14.

PMID:
24462073
17.

Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Trembley JH, Unger GM, Gomez OC, Abedin J, Korman VL, Vogel RI, Niehans G, Kren BT, Ahmed K.

Mol Cell Pharmacol. 2014;6(2):15-25.

18.

Moderate concentrations of supplemental oxygen worsen hypercapnia in obesity hypoventilation syndrome: a randomised crossover study.

Hollier CA, Harmer AR, Maxwell LJ, Menadue C, Willson GN, Unger G, Flunt D, Black DA, Piper AJ.

Thorax. 2014 Apr;69(4):346-53. doi: 10.1136/thoraxjnl-2013-204389. Epub 2013 Nov 19.

PMID:
24253834
19.

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Trembley JH, Unger GM, Korman VL, Tobolt DK, Kazimierczuk Z, Pinna LA, Kren BT, Ahmed K.

Cancer Lett. 2012 Feb 1;315(1):48-58. doi: 10.1016/j.canlet.2011.10.007. Epub 2011 Oct 12.

20.

Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.

Trembley JH, Unger GM, Tobolt DK, Korman VL, Wang G, Ahmad KA, Slaton JW, Kren BT, Ahmed K.

Mol Cell Biochem. 2011 Oct;356(1-2):21-35. doi: 10.1007/s11010-011-0943-x. Epub 2011 Jul 15.

21.

Adopting Guidelines into Clinical Practice: Implementation of Trastuzumab in the Adjuvant Treatment of Breast Cancer in Lower Saxony, Germany, in 2007.

Liebrich C, Unger G, Dlugosch B, Hofmann S, Petry KU.

Breast Care (Basel). 2011;6(1):43-50. Epub 2011 Jan 31.

22.

Influence of updated guidelines on short- and long-term mortality in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).

Vogel B, Hahne S, Kozanli I, Kalla K, Jarai R, Freynhofer M, Smetana P, Nürnberg M, Geppert A, Unger G, Huber K.

Int J Cardiol. 2012 Sep 6;159(3):198-204. doi: 10.1016/j.ijcard.2011.02.073. Epub 2011 Mar 29.

PMID:
21447430
23.

Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience.

Tentzeris I, Jarai R, Farhan S, Wojta J, Schillinger M, Geppert A, Nürnberg M, Unger G, Huber K.

Clin Res Cardiol. 2011 Mar;100(3):191-200. doi: 10.1007/s00392-010-0228-5. Epub 2010 Sep 22.

PMID:
20859742
24.

Comparison between a single-channel nasal airflow device and oximetry for the diagnosis of obstructive sleep apnea.

Rofail LM, Wong KK, Unger G, Marks GB, Grunstein RR.

Sleep. 2010 Aug;33(8):1106-14.

25.

The utility of single-channel nasal airflow pressure transducer in the diagnosis of OSA at home.

Rofail LM, Wong KK, Unger G, Marks GB, Grunstein RR.

Sleep. 2010 Aug;33(8):1097-105.

26.

The role of single-channel nasal airflow pressure transducer in the diagnosis of OSA in the sleep laboratory.

Rofail LM, Wong KK, Unger G, Marks GB, Grunstein RR.

J Clin Sleep Med. 2010 Aug 15;6(4):349-56.

27.

Emergence of protein kinase CK2 as a key target in cancer therapy.

Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, Ahmed K.

Biofactors. 2010 May-Jun;36(3):187-95. doi: 10.1002/biof.96. Review.

28.

Linear separability of gene expression data sets.

Unger G, Chor B.

IEEE/ACM Trans Comput Biol Bioinform. 2010 Apr-Jun;7(2):375-81. doi: 10.1109/TCBB.2008.90.

PMID:
20431156
29.

Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points.

Siller-Matula JM, Tentzeris I, Vogel B, Schacherl S, Jarai R, Geppert A, Unger G, Huber K.

Clin Res Cardiol. 2010 Oct;99(10):645-50. doi: 10.1007/s00392-010-0165-3. Epub 2010 Apr 20.

PMID:
20405134
30.

CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, Arun P, Lu H, Korman V, Unger G, Ahmed K, Van Waes C, Chen Z.

Clin Cancer Res. 2010 Apr 15;16(8):2295-307. doi: 10.1158/1078-0432.CCR-09-3200. Epub 2010 Apr 6.

31.

Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.

Kren BT, Unger GM, Sjeklocha L, Trossen AA, Korman V, Diethelm-Okita BM, Reding MT, Steer CJ.

J Clin Invest. 2009 Jul;119(7):2086-99. doi: 10.1172/JCI34332. Epub 2009 Jun 8.

32.

Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.

Trembley JH, Wang G, Unger G, Slaton J, Ahmed K.

Cell Mol Life Sci. 2009 Jun;66(11-12):1858-67. doi: 10.1007/s00018-009-9154-y. Review.

33.

Short-term hypoxia reduces arterial stiffness in healthy men.

Vedam H, Phillips CL, Wang D, Barnes DJ, Hedner JA, Unger G, Grunstein RR.

Eur J Appl Physiol. 2009 Jan;105(1):19-25. doi: 10.1007/s00421-008-0868-6. Epub 2008 Sep 25.

PMID:
18815804
34.

Protein kinase CK2--a key suppressor of apoptosis.

Ahmad KA, Wang G, Unger G, Slaton J, Ahmed K.

Adv Enzyme Regul. 2008;48:179-87. doi: 10.1016/j.advenzreg.2008.04.002. Epub 2008 Apr 30. Review. No abstract available.

35.

Diagnostic test evaluation of a nasal flow monitor for obstructive sleep apnea detection in sleep apnea research.

Wong KK, Jankelson D, Reid A, Unger G, Dungan G, Hedner JA, Grunstein RR.

Behav Res Methods. 2008 Feb;40(1):360-6.

PMID:
18411561
36.

The harmonization of the regulation of blood products: a European perspective.

Seitz R, Heiden M, Nübling CM, Unger G, Löwer J.

Vox Sang. 2008 May;94(4):267-76. doi: 10.1111/j.1423-0410.2007.01026.x. Epub 2008 Jan 2. Review.

PMID:
18179678
37.

The utility of the AusEd driving simulator in the clinical assessment of driver fatigue.

Desai AV, Wilsmore B, Bartlett DJ, Unger G, Constable B, Joffe D, Grunstein RR.

Behav Res Methods. 2007 Aug;39(3):673-81.

PMID:
17958181
38.

Participation in screening colonoscopy in first-degree relatives from patients with colorectal cancer.

Ruthotto F, Papendorf F, Wegener G, Unger G, Dlugosch B, Korangy F, Manns MP, Greten TF.

Ann Oncol. 2007 Sep;18(9):1518-22.

39.

Antiplatelet drug induced isolated profound thrombocytopenia in interventional cardiology: a review based on individual case reports.

Höchtl T, Pachinger L, Unger G, Geppert A, Wojta J, Harenberg J, Huber K.

J Thromb Thrombolysis. 2007 Aug;24(1):59-64. Epub 2007 Jan 20. Review.

PMID:
17238004
40.

Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry).

Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, Schreiber W, Unger G, Glogar HD, Kaff A, Laggner AN, Maurer G, Mlczoch J, Slany J, Weber HS, Huber K; Vienna STEMI Registry Group.

Circulation. 2006 May 23;113(20):2398-405. Epub 2006 May 15.

PMID:
16702474
41.

CK2 signaling in androgen-dependent and -independent prostate cancer.

Wang G, Ahmad KA, Unger G, Slaton JW, Ahmed K.

J Cell Biochem. 2006 Oct 1;99(2):382-91. Review.

PMID:
16598768
42.

Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light.

Kohlhaas M, Spoerl E, Schilde T, Unger G, Wittig C, Pillunat LE.

J Cataract Refract Surg. 2006 Feb;32(2):279-83.

PMID:
16565005
43.

[Direct and indirect antithrombins in acute coronary syndromes].

Höchtl T, Geppert A, Nürnberg M, Unger G, Speidl W, Wojta J, Huber K.

Wien Klin Wochenschr. 2005 Dec;117(23-24):792-800. Review. German.

PMID:
16437314
44.

Downregulation of CK2 induces apoptosis in cancer cells--a potential approach to cancer therapy.

Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K.

Mol Cell Biochem. 2005 Jun;274(1-2):77-84.

PMID:
16342410
45.

Targeting CK2 for cancer therapy.

Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K.

Anticancer Drugs. 2005 Nov;16(10):1037-43. Review.

PMID:
16222144
46.

Improving surgical wound healing with basic fibroblast growth factor after radiation.

Hom DB, Unger GM, Pernell KJ, Manivel JC.

Laryngoscope. 2005 Mar;115(3):412-22.

PMID:
15744149
47.

Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model.

Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K.

Mol Cancer Res. 2004 Dec;2(12):712-21.

48.

Protein kinase CK2 as regulator of cell survival: implications for cancer therapy.

Unger GM, Davis AT, Slaton JW, Ahmed K.

Curr Cancer Drug Targets. 2004 Feb;4(1):77-84. Review.

PMID:
14965269
49.

Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.

Nübling CM, Unger G, Chudy M, Raia S, Löwer J.

Transfusion. 2002 Aug;42(8):1037-45.

PMID:
12385416
50.

Hepatitis C virus transmission through quarantine fresh-frozen plasma.

Humpe A, Legler TJ, Nübling CM, Riggert J, Unger G, Wolf C, Heermann KH, Köhler M.

Thromb Haemost. 2000 Nov;84(5):784-8.

PMID:
11127856

Supplemental Content

Support Center